Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Ocular Therapeutix's price to sales ratio was 28.1× on Nov 11, 2026, against 38.1× a year earlier. Over the last 5 years it ranged from 3.4× to 44.3×, with a median of 17.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 28.1× | −10.0 |
| 2025 | Dec 31, 2025 | 38.1× | +16.3 |
| 2024 | Dec 31, 2024 | 21.8× | +15.6 |
| 2023 | Dec 29, 2023 | 6.1× | +1.8 |
| 2022 | Dec 30, 2022 | 4.4× | −9.5 |
| 2021 | Dec 31, 2021 | 13.8× | −92.2 |
| 2020 | Dec 31, 2020 | 106.1× | +29.3 |
| 2019 | Dec 31, 2019 | 76.7× | −5.0 |
| 2018 | Dec 31, 2018 | 81.7× | +14.6 |
| 2017 | Dec 29, 2017 | 67.2× | −47.8 |
| 2016 | Dec 30, 2016 | 114.9× | −12.5 |
| 2015 | Dec 31, 2015 | 127.4× | – |
See a number that looks wrong?